Metsera (NASDAQ:MTSR) Shares Gap Down - What's Next?

Key Points

• Metsera Inc. (NASDAQ:MTSR) shares gapped down from a previous closing price of $40.47 to an opening price of $39.01 prior to trading on Monday, with a last traded price of $39.79.
• A number of analysts have recently given Metsera a "buy" rating, with Guggenheim raising their price target from $56.00 to $62.00 and Wells Fargo setting a target of $65.00.
• Metsera, a clinical-stage biopharmaceutical company, focuses on developing next-generation peptides to treat obesity and related conditions with products like MET-097i, MET-233, and MET-224o.

Metsera Inc. (NASDAQ:MTSR - Get Free Report)'s stock price gapped down before the market opened on Monday . The stock had previously closed at $40.47, but opened at $39.01. Metsera shares last traded at $39.79, with a volume of 223,008 shares traded.

Analyst Ratings Changes

Several equities research analysts have commented on MTSR shares. Guggenheim upped their price target on Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, June 10th. Wells Fargo & Company assumed coverage on Metsera in a research note on Friday, June 20th. They set an "overweight" rating and a $65.00 price objective on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $55.00.

Metsera Stock Up 5.8%

The firm has a 50 day moving average price of $32.44.

Metsera (NASDAQ:MTSR - Get Free Report) last announced its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On Metsera

A number of hedge funds have recently bought and sold shares of the company. Alphabet Inc. acquired a new position in Metsera in the first quarter worth about $135,059,000. T. Rowe Price Investment Management Inc. acquired a new stake in Metsera during the first quarter worth about $78,748,000. Wellington Management Group LLP acquired a new stake in Metsera during the first quarter worth about $65,382,000. Alpha Wave Global LP acquired a new stake in Metsera during the first quarter worth about $64,894,000. Finally, Price T Rowe Associates Inc. MD acquired a new stake in Metsera during the first quarter worth about $42,395,000.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.